Base editing and gene therapy for xeroderma pigmentosum XPA variants

Overview

Xeroderma pigmentosum (XP) results from mutations in DNA repair genes like XPA, leading to severe photosensitivity and increased skin cancer risk. Current treatments are limited to UV light avoidance, restricting patients' quality of life. This research explores base editing and gene therapy as potential curative solutions for XP, specifically targeting prevalent XPA mutations found in Japan. By correcting these mutations in epidermal keratinocytes or pluripotent cells, this approach aims to restore DNA repair capabilities and reduce cancer risk.

Technical specifications

• Mutations targeted: Common XPA point mutations such as IVS3-1G>C, c.348T>A, and c.682C>T.
• Methodology: Uses base editing and prime editing techniques, including a special Cas9 conjugated with reverse transcriptase and guide RNA.
• Cell sources: Epidermal keratinocytes from skin biopsies or induced pluripotent patient cells.
• Delivery method: AAV transduction for nucleic acid delivery, tested in cultured cells.
• Validation: Proof-of-principle established through ELISA assays measuring DNA lesion correction.

Technology readiness level

The technology is at TRL 2, indicating experimental proof of concept is underway in controlled settings, with ongoing efforts to establish feasibility in cultured patient cells.